Vigmed AB signs distribution agreement for Australia and New Zealand.
Vigmed AB expands their strategic market penetration initiatives and signs an exclusive distribution agreement for Australia and New Zealand with Device Technologies Australia Pty Ltd.
Vigmed announced today that they have signed an exclusive distribution agreement for the first markets in the Asia Pacific region. Device Technologies is the chosen partner to be responsible for introducing the Vigmed brand to the Australian and New Zealand markets.
“We are extremely pleased to have Device Technologies as our partner in this region. As with Vigmed’s other partners, this will be the start of a close sales, marketing and development cooperation”, says Vigmed CEO, Finn Ketler.
“Device Technologies has substantial experience of this particular geographical market, specific experience of the infusion therapy market and excellent reputation for quality sales and support. The fact that they have chosen our safety products over other manufacturers’ gives us great confidence when entering these markets”, says Vigmed Sales Director Asia Pacific, Mike Dooley.
“The Vigmed products offer us a quality, cost effective and competitive solution to the issue of needlestick injuries and healthcare workers safety”, comments Ruth Roberts, Device Technologies Business Development Manager. “This cooperation fits well with our aim to enable superior health outcomes for patients, by providing them with access to the best medical systems available worldwide."
The market launch will take place following completion of registration activities, which are based on existing CE certification.
For further information contact:
CEO, Finn Ketler +46 42 600 5311 or Sales Director, Mike Dooley +46 42 600 5317
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor